Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022

被引：0
|
作者：
Kamat, Samir [1 ]
Ungar, Benjamin [2 ]
Agarwal, Aneesh [1 ]
Wan, Joy [3 ]
Ross, Joseph S. [4 ]
Gupta, Ravi [5 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Med Educ, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
[3] Johns Hopkins Univ, Dept Dermatol, Sch Med, Baltimore, MD USA
[4] Yale Sch Med, Dept Internal Med, Sect Gen Internal Med, New Haven, CT USA
[5] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA
来源：
JAMA DERMATOLOGY | 2024年 / 160卷 / 02期
关键词：
D O I：
10.1001/jamadermatol.2023.5036
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This cross-sectional study characterizes the frequency and degree of innovation of new dermatologic drugs approved by the US Food and Drug Administration (FDA) from 2012 to 2022.
引用
收藏
页码：226 / 229
页数：4
相关论文
共 50 条
  • [1] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    [J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 1619 - 1632
  • [2] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
    Kayki-Mutlu, Gizem
    Aksoyalp, Zinnet Sevval
    Wojnowski, Leszek
    Michel, Martin C.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (08) : 1619 - 1632
  • [3] A review of new drugs approved by the food and drug administration in 2022
    Swaminathan, Arjun
    Vijayakumar, A. E.
    Nikhithaa, P.
    [J]. JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2023, 12 (10) : 2223 - 2229
  • [4] An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the US Food and Drug Administration, 2012-2022
    Collins, Grace
    McKelvey, Brittany
    Andrews, Hillary S.
    Allen, Jeff D.
    Stewart, Mark D.
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (05) : 937 - 941
  • [5] Commentary on "A review of new drugs approved by the food and drug administration in 2022"
    Sharma, Kopal
    Sharma, Amit
    Kapadia, Rupa
    [J]. JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2024, 13 (03) : 1133 - 1133
  • [6] Role of US military research programs in the development of US Food and Drug Administration - Approved antimalarial drugs
    Kitchen, LW
    Vaughn, DW
    Skillman, DR
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) : 67 - 71
  • [7] COMBINED ADULT AND PEDIATRIC TRIALS IN ORPHAN DRUGS APPROVED BETWEEN 2012 AND 2018 SUBMITTED TO THE US FOOD AND DRUG ADMINISTRATION.
    Tanaudommongkon, I.
    Park, K.
    Wu, J.
    Kim, C.
    Green, D.
    Burckart, G.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S105 - S105
  • [8] Trends in amorphous solid dispersion drug products approved by the US Food and Drug Administration between 2012 and 2023
    Moseson, Dana E.
    Tran, Trong Bien
    Karunakaran, Bharathi
    Ambardekar, Rohan
    Hiew, Tze Ning
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS-X, 2024, 7
  • [9] Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
    Wallach, Joshua D.
    Egilman, Alexander C.
    Dhruva, Sanket S.
    McCarthy, Margaret E.
    Miller, Jennifer E.
    Woloshin, Steven
    Schwartz, Lisa M.
    Ross, Joseph S.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 361
  • [10] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
    Kayki-Mutlu, Gizem
    Aksoyalp, Zinnet Sevval
    Wojnowski, Leszek
    Michel, Martin C.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (08) : 867 - 885
12345